The Institute of Clinical Research (ICR) has further strengthened its commitment to developing professionals within the industry by enhancing its eLearning education programme.
The programme now features 10 eLearning modules, all upgraded to include Flash technology offering interactive education courses for clinical research professionals. Each course is available through the ICR website allowing individuals to study at a convenient pace and around their work commitments.
New to ICR’s eLearning range are Practical Monitoring, which provides an insight into the practical requirements of a Monitor in the conduct of clinical trials, and GCP Compliance in Document Management and Archiving, which examines the why, what, who and when of paper and electronic archiving. The latter is presented in association with specialist CRO, Phlexglobal.
Alongside these modules, ICR is also introducing two new courses designed to help new or existing staff develop their careers. Entitled So You Want to be a CRA? and How to Get a Job as a CRA, these modules lead participants through the essential skills required to be a successful CRA and provide guidance on how to approach the application process.
These new courses will join the existing modules entitled ICH GCP for Investigators, ICH GCP for Sponsors, Principles of ICH GCP, Data Protection and Clinical Research in the UK, GCP Directive and EU Clinical Trials Directive.
Sue Fitzpatrick, education manager at the ICR, is excited about launching the new modules. She said: “We have extended our eLearning programme to incorporate more areas of clinical research and to help our members further their careers.
“Our wide range of courses demonstrates how the ICR is monitoring current trends in the clinical research industry and is offering valuable remote training for clinical researchers. The courses are available online allowing students to study around their own personal and work commitments.”
The ICR operates a comprehensive training programme with both public and in-house courses plus its eLearning and distance learning. Each course carries Continuing Professional Development (CPD) points allowing members to development their knowledge and skills.
A further 10 new eLearning modules will be available during 2009.
For further details about eLearning and other training opportunities from the ICR, log onto the website at www.icr-global.org/learning or call 01628 536967.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.